Data completeness
2/8 — Basic
CHLOROMYCETIN (chloramphenicol) by Pfizer is clinical pharmacology chloramphenicol is a broad-spectrum antibiotic originally isolated from streptomyces venezuelae . Approved for surface ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol-susceptible organisms.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHLOROMYCETIN (chloramphenicol) is a broad-spectrum bacteriostatic antibiotic that treats surface ocular infections of the conjunctiva and cornea. It works by inhibiting bacterial protein synthesis through interference with amino acid transfer to ribosomes. The cream formulation is applied topically and demonstrates minimal resistance development in susceptible organisms.
Pre-Launch
Pre-launch stage offers opportunity to build brand infrastructure in a niche ophthalmic indication with minimal commercial data available; early-stage roles in medical affairs and market access are critical.
Mechanism of Action
Clinical Pharmacology Chloramphenicol is a broad-spectrum antibiotic originally isolated from Streptomyces venezuelae . It is primarily bacteriostatic and acts by inhibition of protein synthesis by interfering with the transfer of activated amino acids from soluble RNA to ribosomes. It has been…
Worked on CHLOROMYCETIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.